Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptiRiMoxTB: Optimized Dose of Rifampicin and Moxifloxacin for Drug Susceptible Pulmonary Tuberculosis
NCT05575518Phase 3Completed
- Start
- Aug 2023
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rifampicin, moxifloxacin in Tuberculosis (TB). Started Aug 2023; status: completed.
02
Drugs
rifampicinmoxifloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05575518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05575518.